Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

2.8%

1 terminated out of 36 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed with results

Key Signals

86% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (10)
P 1 (2)
P 2 (11)

Trial Status

Recruiting14
Unknown9
Completed6
Not Yet Recruiting3
Withdrawn2
Terminated1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT06510699Phase 2Recruiting

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

NCT07463976Not Yet Recruiting

variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway

NCT07440290Phase 2Not Yet RecruitingPrimary

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

NCT04174053Not ApplicableCompletedPrimary

Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units

NCT06395220CompletedPrimary

Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation

NCT04068597Phase 1RecruitingPrimary

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT05786716Phase 2RecruitingPrimary

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

NCT05770037Phase 2RecruitingPrimary

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

NCT05770544Phase 2RecruitingPrimary

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

NCT05722886Phase 2RecruitingPrimary

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

NCT05768178Phase 2RecruitingPrimary

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

NCT06988475Phase 2Recruiting

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

NCT06814405Not ApplicableRecruitingPrimary

Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

NCT06787326Active Not RecruitingPrimary

Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia

NCT05298930Not ApplicableCompletedPrimary

Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation

NCT05159245Phase 2Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

NCT04298892Unknown

Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

NCT06481527Not Yet Recruiting

Seen and Be Heard: Ensuring Fair Cancer Care for All Children

NCT05678621Phase 2RecruitingPrimary

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

NCT05695638Recruiting

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Scroll to load more

Research Network

Activity Timeline